Atractyloside

A glycoside of a kaurene type diterpene that is found in some plants including Atractylis gummifera (ATRACTYLIS); COFFEE; XANTHIUM, and CALLILEPIS. Toxicity is due to inhibition of ADENINE NUCLEOTIDE TRANSLOCASE.

Also Known As:

Networked: 89 relevant articles (8 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Gao, Qin: 8 articles (01/2012 - 01/2005)
2.	Xia, Qiang: 7 articles (11/2009 - 01/2005)
3.	Krolikowski, John G: 4 articles (09/2008 - 12/2005)
4.	Pagel, Paul S: 4 articles (09/2008 - 12/2005)
5.	Warltier, David C: 4 articles (09/2008 - 12/2005)
6.	Weihrauch, Dorothee: 4 articles (09/2008 - 12/2005)
7.	Bruce, Iain C: 4 articles (09/2006 - 01/2005)
8.	Zhang, Shi-Zhong: 3 articles (10/2019 - 12/2005)
9.	Xu, Zhelong: 3 articles (11/2016 - 05/2006)
10.	Faghihi, Mahdieh: 3 articles (08/2015 - 11/2010)

Related Diseases

1.	Ischemia 05/26/1976 - "Intracoronary infusion of atractyloside resulted in physiological, biochemical, and ultrastructural changes similar to those seen with ischemia. " 07/06/2015 - "Sprague Dawley rats (N = 60) were randomly divided into five groups of 12 rats each: control, ischemia/reperfusion (I/R), melatonin treatment (MT), melatonin treatment + atractyloside (MT+ATR), and atractyloside (ATR). " 06/13/2006 - "In isolated ventricular myocytes, pretreatment with Pue prevented ischemia-induced cell death and depolarization of the mitochondrial membrane, and atractyloside and 5-hydroxydecanoate attenuated the effects of Pue. " 03/01/2005 - "To examine the role of MPT pores, mice were administered atractyloside (Atr; 25 mg/kg i.v.), which induces adenine nucleotide translocase-dependent MPT, 20 min before ischemia. " 02/01/1996 - "Although atractyloside-inhibitable adenine nucleotide translocase activity was markedly decreased during sustained ischemia in both groups, its activity was significantly higher after reperfusion in the IP group. "
2.	Infarction (Infarctions) 10/01/2007 - "In addition, the PTP opener atractyloside (20 microM) and the Bcl-2 inhibitor ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA14-1) (20 microM) abrogated CDZ-induced reduction of infarct size. " 05/02/2003 - "Finally, administration of the pore opener atractyloside significantly attenuated the infarct-sparing effect of PKCepsilon transgenesis. " 01/01/2016 - "Also, atractyloside abolished infarct size reduction of morphine completely (65±9%; P<0.05 vs. M-PC) but had no influence on infarct size itself (64±5%; P>0.05 vs. Con). " 07/01/2011 - "In addition, the anti-infarct effect by M-Post was also totally blocked by the MPTP opener atractyloside (26.3 ± 5.2%, P < 0.05). " 11/01/2010 - "Administration of mitoPTP activator atractyloside attenuated the effect of ethanol postconditioning, LDH release and infarct size were increased, and the recovery of hemodynamic parameters was inhibited. "
3.	Wounds and Injuries (Trauma) 05/01/2013 - "Dex preconditioning markedly improved the myocardial viability and cardiac function (P<0.01), which were reversed by the treatment with both atractyloside (20 μmol/L before ischemia), an opener of mPTP, and 5-hydroxydecanoate (100 μmol/L at the beginning of reperfusion), an inhibitor of mitoKATP, for 20 min. Dex has protective effect against I/R injuries in isolated rat hearts, which may be related to inhibiting the opening of mPTP at the beginning of reperfusion and activating mitoKATP before ischemia."
4.	Myocardial Infarction 11/01/2010 - "Seven groups (n = 6) of rats were randomly studied: (I) control: surgical procedure was performed with no ischemia/reperfusion, (II) ischemia/reperfusion: hearts underwent regional ischemia/reperfusion, (III) early phenylephrine: phenylephrine (50 μM) was perfused for 5 min prior to ischemia/reperfusion, (IV) late phenylephrine: rats were treated with phenylephrine (10 mg/kg, i.p) 24 h prior to ischemia/reperfusion, (V) early phenylephrine+atractyloside: hearts were perfused with phenylephrine as in group III and then atractyloside (20 mM) 5 min before reperfusion for 20 min, (VI) late phenylephrine+atractyloside: hearts were treated with phenylephrine as in group IV and then received atractyloside (20 mM), 5 min before reperfusion for 20 min, (VII) atractyloside-IR group: hearts were perfused with atractyloside (20 mM) 5 min before reperfusion for 20 min. Compared with ischemia/reperfusion group, perfusion of phenylephrine in early and late phases decreased myocardial infarct size (% of ischemia zone), reduced creatine kinase-MB (CK-MB) in the coronary effluent, and improved cardiac function. "
5.	Diarrhea 06/01/2022 - "Atractyloside-A ameliorates spleen deficiency diarrhea by interfering with TLR4/MyD88/NF-κB signaling activation and regulating intestinal flora homeostasis." 06/01/2022 - "Atractyloside-A (AA) is one of the main components of Atractylodes Lancea(Thunb.) DC., which acts on the gastrointestinal tract and has therapeutic effects on diarrhea. "

Related Drugs and Biologics

1.	5-hydroxydecanoic acid
2.	Mitochondrial Permeability Transition Pore
3.	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
4.	KATP Channels
5.	Adenosine Triphosphate (ATP)
6.	mitochondrial K(ATP) channel
7.	NS 1619
8.	MB Form Creatine Kinase
9.	Polyamines
10.	Phenylephrine (Neo-Synephrine)

Related Therapies and Procedures

1.	Operative Surgical Procedures
2.	Ischemic Postconditioning
3.	Intravenous Injections